bridging fibrosis

bridging fibrosis

A term for the presence of bands of varying thickness (the wider the bands, the more advanced the disease) of fibrous tissue and collagen seen by low-power light microscopy, which span (connect) portal spaces and/or centrilobular spaces in patients with evolving cirrhosis.
References in periodicals archive ?
Data from the oral presentation further revealed that of the patients who had biopsies at baseline, 47% (15/32) had bridging fibrosis (defined as Ishak score 3 or 4) and an additional 31% (10/32) of patients had cirrhosis.
Further, "the treatment regimen was highly effective in patients with a historically poor treatment response, including blacks, patients with bridging fibrosis or cirrhosis, and patients with high HCV RNA levels.
The former group showed a high degree of bridging fibrosis that was absent in the latter (Fig.
MPH, from the National Cancer Institute (NCI), included 766 participants who had hepatitis C-related bridging fibrosis or cirrhosis and failed to respond to standard treatment of the anti-viral drugs peginterferon and ribavirin.
13) proposed a simple and elegant model of AST-to-platelet ratio index (APRI), which predicted bridging fibrosis as determined by the Ishak scoring system, with an AUC of 0.
A percutaneous needle biopsy of the liver showed loss of normal hepatic architecture, bridging fibrosis, and micronodule formation that was confirmed by trichrome stain.
Liver biopsy is the primary method of establishing which patients to treat, based upon the amount of bridging fibrosis present at the time of the biopsy.
Patients less likely to benefit from retreatment after failing a course of therapy include those with previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, or HCV genotype 1 infection.
In the present study, fragmented biopsies were associated with false-positive fibrosis, suggesting that pathologists in this setting could overestimate bridging fibrosis.
Non-cirrhotic patients, including patients with bridging fibrosis, receiving Infergen 15 [acute accent]g daily experienced 25 percent viral negativity at 24 weeks (36 percent by bDNA).
About 92% of the patients included in the intent-to-treat analysis had baseline HCV RNA levels of 800,000 IU/mL or higher, and 43% had cirrhosis or bridging fibrosis.
This sub-analysis of the international APRICOT trial investigates the efficacy and safety of Pegasys plus Copegus in hepatitis C patients co- infected with HIV with cirrhosis or bridging fibrosis.